Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regencell Bioscience ( (RGC) ) just unveiled an update.
On March 30, 2026, Regencell Bioscience filed a Form 6-K reporting that material documents were incorporated by reference into its effective shelf registration statement on Form F-3 and related prospectus supplement filed the same day. The filing includes a sales agreement with Univest Securities for the potential issuance and sale, from time to time, of Regencell’s ordinary shares under an at-the-market offering program, along with a Cayman Islands tax opinion and related legal consent, positioning the company to flexibly raise equity capital in U.S. markets.
More about Regencell Bioscience
Regencell Bioscience Holdings Limited is a Cayman Islands–incorporated bioscience company listed on Nasdaq and headquartered in Hong Kong. The company focuses on developing and commercializing therapies, with its ordinary shares registered for offering in the U.S. capital markets.
Average Trading Volume: 416,048
Technical Sentiment Signal: Buy
Current Market Cap: $12.69B
For a thorough assessment of RGC stock, go to TipRanks’ Stock Analysis page.